Nutriband Secures $5.3 Million Through Warrant Exercises to Advance Abuse-Deterrent Fentanyl Patch Development
Nutriband Inc. has raised $5.3 million from warrant exercises to fund the clinical development and FDA submission of AVERSA Fentanyl, potentially the world's first abuse-deterrent opioid patch with estimated peak annual U.S. sales of $80-200 million.
Nutriband Inc. (NASDAQ: NTRB) has generated $5,306,000 in proceeds through the exercise of warrants at a strike price of $6.43, providing critical funding for the advancement of its AVERSA Fentanyl transdermal patch. The capital will support the remaining clinical development and submission of a New Drug Application to the U.S. Food and Drug Administration for what could become the world's first opioid patch with abuse deterrent properties.
The financial injection comes at a crucial time for the pharmaceutical development company, which specializes in creating abuse-deterrent pharmaceutical products. AVERSA Fentanyl incorporates proprietary technology designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. According to a 2022 Health Advances market analysis report, the product is estimated to reach peak annual U.S. sales between $80 million and $200 million, representing significant commercial potential in addressing the ongoing opioid crisis.
The warrant exercise demonstrates investor confidence in Nutriband's technology and development pipeline. The AVERSA technology platform can be incorporated into any transdermal patch containing drugs with abuse potential, positioning the company to address broader market opportunities beyond fentanyl products. The funding will accelerate the regulatory submission process and potentially bring this innovative abuse-deterrent solution to market sooner.
For investors seeking additional information, the company maintains a newsroom at https://ibn.fm/NTRB where updates regarding Nutriband's progress are available. The development of abuse-deterrent formulations represents an important advancement in pharmaceutical safety, particularly given the ongoing challenges with opioid misuse and addiction. Successful development and approval of AVERSA Fentanyl could establish new standards for transdermal opioid delivery systems while addressing critical public health concerns surrounding prescription drug abuse.